Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease with a median survival time of 3–5 years. Inaccurate diagnosis, limited clinical therapy and high mortality together indicate that the development of effective therapeutics for IPF is an urgent need. In recent years, it was reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qi, Tang, Bixi, Sun, Dandan, Dong, Ying, Ji, Yinchun, Shi, Huanyu, Zhou, Liwei, Yang, Yueyue, Luo, Menglan, Tan, Qian, Chen, Lin, Dong, Yue, Li, Cong, Xie, Rongrong, Zang, Yi, Shen, Jingkang, Xiong, Bing, Li, Jia, Chen, Danqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279635/
https://www.ncbi.nlm.nih.gov/pubmed/35847490
http://dx.doi.org/10.1016/j.apsb.2021.11.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279635/
https://www.ncbi.nlm.nih.gov/pubmed/35847490
http://dx.doi.org/10.1016/j.apsb.2021.11.012

Ejemplares similares